INVITRO EFFECTS OF CHELIDONIUM-MAJUS L ALKALOID THIOPHOSPHORIC ACID CONJUGATES (UKRAIN) ON THE PHENOTYPE OF NORMAL HUMAN-LYMPHOCYTES

Authors
SLESAK B NOWICKY JW HARLOZINSKA A
Citation
B. Slesak et al., INVITRO EFFECTS OF CHELIDONIUM-MAJUS L ALKALOID THIOPHOSPHORIC ACID CONJUGATES (UKRAIN) ON THE PHENOTYPE OF NORMAL HUMAN-LYMPHOCYTES, Drugs under experimental and clinical research, 18, 1992, pp. 17-21
Citations number
16
Categorie Soggetti
Pharmacology & Pharmacy
Journal title
Drugs under experimental and clinical research → ACNP
ISSN journal
03786501
Volume
18
Year of publication
1992
Supplement
S
Pages
17 - 21
Database
ISI
SICI code
0378-6501(1992)18:<17:IEOCLA>2.0.ZU;2-N
Abstract
Several plant-derived drugs are used in medical oncology (1-3). The th iophosphoric acid-alkaloid derivative from the plant Chelidonium majus L. (Ukrain) has been produced since 1978 by Nowicky. (Austrian Patent No. 354644, Vienna, 25 January 1980). It has been reported that this drug may exert therapeutic effects in cancer patients by modulating th eir immune systems (4, 5-8). The aim of this study was to evaluate in vitro the possibility that Ukrain may influence the phenotype of lymph ocyte subpopulations isolated from healthy donors.